Skip to main content

$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
Register to track MSB and receive email alerts.
Subject
MSB Ann: Appendix 3G, Appendix 3H and Appendix 3Y

MSB Ann: Amended Constitution

MSB Ann: Results of Meeting

MSB Article: NZ dollar jumps after RBNZ lifts rates by record 0.75pc

MSB Article: RBNZ lifts rates 0.75pc to 4.25pc in record high increase

MSB Ann: Chairman's Address to Shareholders

MSB Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel

MSB Ann: MSB Q1 Financial Results and Operational Highlights

MSB Ann: CEO First Quarter Results and 2022 AGM Presentation

MSB Ann: First Quarter Financial Results on Form 6-K

MSB Ann: Mesoblast First Quarter Financial Results Webcast

MSB Ann: Removal of Amendment to Constitution About Virtual Meetings

MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

MSB Ann: Notice of Annual General Meeting and Proxy Form

MSB Ann: Annual Report to Shareholders

MSB Ann: Appendix 4G and Corporate Governance Statement

MSB Ann: Notification of cessation of securities - MSB

MSB Ann: Submits New Information to FDA IND File for SR-aGVHD

MSB Ann: Change of Director's Interest Notice

MSB Ann: Change of Director's Interest Notice

MSB Ann: MSB Annual Financial Results and Operational Highlights

MSB Ann: Annual Financial Results Presentation

MSB Ann: Preliminary Final Report

MSB Ann: Mesoblast 2022 Full Year Financial Results Webcast

MSB Ann: Director Appointment

MSB Ann: Initial Director's Interest Notice

MSB Ann: Final Director's Interest Notice

MSB Ann: Ceasing to be a substantial holder - Tiga Trading Pty Ltd

MSB Ann: Ceasing to be a substantial holder from TEK

MSB Ann: Ceasing to be a substantial holder from TOP

MSB Ann: Change in substantial holding

MSB Ann: Cleansing Notice

MSB Ann: Appendix 2A

MSB Ann: Appendix 3B

MSB Ann: US$45 Million Private Placement to Major Shareholders

MSB Ann: Reinstatement to Quotation

MSB Ann: Voluntary Suspension

MSB Ann: Trading Halt

MSB Ann: Pause in Trading

MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

MSB Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE

MSB Ann: Appendix 3H and Appendix 3Y

MSB Ann: Rexlemestrocel-L to be Highlighted on Heart Failure Panel

MSB Article: Dogs rule in unsteady start to new financial year

MSB Ann: Mesoblast CLBP Event with Key Opinion Leaders

MSB Ann: Chronic Low Back Pain KOL Event Presentation

MSB Ann: Litigation Update

MSB Article: Mesoblast accused of misleading investors

MSB Ann: Mesoblast to Host KOL Event on Chronic Low Back Pain

MSB Ann: Third Quarter Results Presentation

Register to track MSB and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
OPT
PAR
PYC
RAC
TLX